CCK2R targeting Theranostic (Starget Pharma)

N/A

Report date: 2025/04/14 11:01:46

NME

Base Information

Drug NameCCK2R targeting Theranostic (Starget Pharma)

Drug Alias NameCCK2R Theranostic

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Synthetic peptide

Mechanisms of ActionCholecystokinin B receptor modulators

TargetsCholecystokinin B receptor

Therapy Area/IndicationsMedullary thyroid cancer (MTC)Small Cell Lung CarcinomaGastrointestinal Stromal Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesStarget Pharma Ltd

China Registration ClassN/A

Develop Information

Active CompaniesStarget Pharma Ltd

Inactive CompaniesN/A

Active IndicationsMedullary thyroid cancer (MTC)Small Cell Lung CarcinomaGastrointestinal Stromal Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A